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Abstract
There is a close relationship between the brain and the
endocrine system. The brain expresses receptors for sex
steroids and is capable of metabolizing these hormones.
We explored (1) sex diﬀerences in homovanillic acid
(HVA), a metabolite of the neurotransmitter dopamine,
and (2) the eﬀects of cross-sex steroid administration in
transsexual subjects. First, we compared plasma HVA
levels between 38 male and 34 female healthy volunteers
(not using hormone replacement therapy) of a mean age of
72 years (range 65–84 years). Secondly, we measured
plasma HVA levels in 15 male-to-female transsexuals
treated with 100 µg ethinyl estradiol/day and 100 mg
cyproterone acetate/day for 4 months, and in 17 female-
to-male transsexuals treated with testosterone esters
(250 mg/2 weeks i.m. for 4 months). Plasma HVA levels
were lower in elderly men than in elderly postmenopausal
women (geometric mean 25·4 nmol/l (percentile (P)10
4·9; P90 69·8) vs 39·0 nmol/l (19·0; 76·1); P=0·027). In
transsexuals before cross-sex hormone administration, gen-
etic males also had lower plasma levels of HVA than
genetic females (geometric mean 14·8 nmol/l (P10 7·0; P90
35·0) vs 34·3 nmol/l (21·8; 61·4); P<0·001). Cross-sex
hormone administration did not aﬀect plasma HVA in
either group (P>0·5). The pretreatment sex diﬀerence in
plasma HVA was unaﬀected after 4 months of cross-sex
hormone administration (P=0·003). The sex diﬀerence in
plasma HVA was not reversed by cross-sex hormone
administration in transsexuals, and was also preserved in
elderly subjects. This indicated that diﬀerences in
dopamine gene expression were largely unaﬀected by
exposure to sex hormone levels in adulthood, but must
rather be explained by a sex diﬀerence in genetic factors or
by the organizing eﬀects of sex hormones during early
development.
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Introduction
Sex diﬀerences in schizophrenia, with an earlier onset
(Hambrecht et al. 1992, Albus & Maier 1995, Szymanski
et al. 1995, Halbreich & Kahn 2003) and a higher
prevalence (Aleman et al. 2003) in men than in women,
may indicate that sex hormones are implicated in its
expression, etiology and course. The brain contains recep-
tors (Kruijver et al. 2001, 2003, Toran-Allerand 2004) for
androgens and estrogens, and is capable of synthesizing and
metabolizing these steroids (Puy et al. 1995, Poletti &
Martini 1999, Stoﬀel-Wagner 2003, Altman 2004).
Dopamine is synthesized from tyrosine by dopaminergic
neurons, and is also the precursor to norepinephrine in
noradrenergic nerves. Dopamine is metabolized in the
brain, liver and kidney to its inactive metabolite homo-
vanillic acid (HVA; Fig. 1), and in human (Amin et al.
1995, Amin et al. 1998) and animal (Bacopoulos et al.
1979) research its plasma concentration was found to be
indicative of brain dopamine turnover. Plasma HVA is not
only elevated in neuroblastomas and pheochromacytomas,
but also in schizotypical personality disorders (Siever et al.
1991). In some (Pickar et al. 1986, Davidson & Davis
1988, Maas et al. 1988, Davidson et al. 1991, Koreen et al.
1994, Sumiyoshi et al. 1997a) but not all (Sumiyoshi et al.
1997b) studies, the baseline and/or change in plasma HVA
was related to psychopathology and treatment response in
schizophrenic patients.
Sex steroids have been found to aﬀect neurotransmitters
and neurotransmitter receptors of the dopaminergic sys-
tems in complex ways, at least in cell and animal studies
(Becker 1999, Eaton et al. 1999, Andersen et al. 2002,
Landry et al. 2002, Halbreich & Kahn 2003, D’Astous
et al. 2004). In humans, the potential eﬀects of sex
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hormone administration on dopaminergic activity have not
yet been studied extensively (Lobo et al. 1984, Hannan
et al. 1991, Paoletti et al. 2001). Administration of testos-
terone, which endogenously is partially aromatized to
estrogens, did not aﬀect serum HVA in a small group of
men (Hannan et al. 1991), although nandrolone decanoate,
only a weakly aromatizable synthetic anabolic steroid, did
increase serum HVA. A consistent sex diﬀerence has been
described for plasma HVA levels. Higher plasma levels of
HVA are found in female patients with schizophrenia
(Koreen et al. 1994, Davila et al. 1995, Szymanski et al.
1995, Sumiyoshi et al. 1997b), in female patients with
psychotic disorders (Bowers et al. 1983, Bowers & Swigar
1987), in female patients with tardive dyskinesia (Glazer
et al. 1983), as well as in healthy female controls (Koreen
et al. 1994, Sumiyoshi et al. 1997b) as compared with their
male counterparts. This sex diﬀerence in plasma HVA
implies sex diﬀerences in dopamine metabolism but not
necessarily in dopamine levels.
Studies in transsexual subjects have shown that cross-sex
hormones aﬀect psychological variables of aggression,
mood, sexual motivation and sex-related cognitive func-
tions, such as verbal fluency and visuospatial functions
(Van Goozen et al. 1995, Slabbekoorn et al. 1999). Studies
of the brains of transsexuals have shown that certain sex
dimorph areas of the brain have a diﬀerentiation of the
opposite sex (female in male-to-female transsexuals and
vice versa). These anatomical brain structures were not
aﬀected by the administration of cross-sex hormones
(Zhou et al. 1995, Kruijver et al. 2000). In the present
study, we have investigated whether changes in sex
hormones aﬀect the sex diﬀerence in plasma HVA, to test
the hypothesis as to whether human dopamine metabolism
is under sex steroidal influence. Blood samples were
collected as part of a study on the eﬀects of sex hormones
on cardiovascular risk factors (Giltay et al. 2000, 2003). We
measured fasting plasma HVA levels because of the better
reproducibility and smaller variability as compared with
urinary HVA (Donnelly et al. 1996, Amin et al. 1998). It
is also a less invasive approach than sequentially obtaining
cerebrospinal fluid.
Materials and Methods
First, the sex diﬀerence in HVA and 5-hydroxy-
indoleacetic acid (5-HIAA) were studied in 38 male and
34 female healthy volunteers of the Arnhem Elderly
Study, a population-based cohort study that started in 1991
(Giltay et al. 2004). In total, 641 independently living men
and women aged 65–84 years in the city of Arnhem
agreed to have a venipuncture. Plasma HVA and 5-HIAA
was assessed in a random sample of 72 subjects. None of
these postmenopausal women were using hormone re-
placement therapy. The body mass index (BMI; weight/
height2) was assessed. All subjects provided written in-
formed consent. The study was approved by the ethical
committee of Wageningen University.
Secondly, the eﬀects of cross-sex hormone admin-
istration on HVA and 5-HIAA were studied in transsexual
subjects in blood samples collected from 1996 to 1998
(Giltay et al. 2000, 2003). Psychological criteria for the
diagnosis and treatment followed the guidelines provided
by the Harry Benjamin International Gender Dysphoria
Association. Fifteen male-to-female (MF) transsexuals
were treated with ethinyl estradiol (Lynoral; 100 µg/day;
Organon, Oss, The Netherlands) in combination with
cyproterone acetate (Androcur; 100 mg/day; Schering,
Figure 1 Role of catechol-O-methyltransferase (COMT)-mediated methylation in dopamine metabolism. The major detoxification pathway
(i.e. metabolizing dopamine to inactivate metabolites) involves O-methylation at the meta-hydroxyl group and oxidative deamination.
O-Methylation is catalyzed by the enzyme COMT and oxidative deamination is catalyzed by MOA, primarily MAO B. HVA is the end
product of dopamine metabolism and can be used as a marker of dopamine turnover. Methionine forms S-adenosylmethionine (SAM),
which serves as the methyl donor to dopamine (and other compounds). Homocysteine, which is formed during this metabolism of
methionine, is metabolized back into methionine through one of two remethylation pathways, one of which using folate as a cofactor.
DOPA, 3,4-dihydroxyphenylalanine; DOPAC, 3,4-dihydroxyphenylacetic acid.
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Berlin, Germany), an anti-androgen that blocks androgen
receptors. Seventeen female-to-male (FM) transsexuals
were treated with testosterone esters (Sustanon; 250 mg/2
weeks i.m.; Organon) according to our standard treatment.
To monitor the anabolic/catabolic eﬀects on body com-
position, the BMI was assessed, and lean body mass and
total body fat were estimated using bioelectrical impedance
analysis (BIA 101/S; RJL Systems, Clinton Twp, MI,
USA). Informed consent was obtained from all subjects,
and the study was conducted according to the principles of
the Declaration of Helsinki and approved by the Ethical
Review Committee of the Vrije Universiteit University
Medical Center.
Laboratory tests
A single non-fasting blood sample was first obtained from
elderly subjects. Venipuncture was performed between
0800 and 1730 h using citrate collection tubes. Samples
were stored at 80 C, and only thawed once before
analysis. Secondly, in transsexual subjects, blood was
sampled before and 2 and 4 months after initiation of
cross-sex hormone administration. Blood was drawn from
genetic women before testosterone treatment between
days 5 and 9 of the follicular phase and again during
testosterone treatment, within 5 to 9 days after the
testosterone injection. All blood was sampled after a 12-h
fast, immediately placed on ice, centrifuged at 3500 g for
30 min at 4 C, stored within 1 h at –80 C and never
thawed until analysis. EDTA plasma samples (Becton
Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA)
were obtained. Serum measurements were made of 17-
estradiol (by radioimmunoassay; Sorin Biomedica, Salug-
gia, Italy) and testosterone (by radioimmunoassay; Coat-
A-Count; Diagnostic Products, Los Angeles, CA, USA),
luteinizing hormone (LH; by immunometric lumi-
nescence assay; Amerlite; Amersham Pharmacia Biotech,
Aylesbury, Bucks, UK) and follicle-stimulating hormone
(FSH; by immunometric luminescence assay; Amerlite).
Since estrogens increase the secretion of prolactin by the
pituitary gland and prolactin release is tonically inhibited
by dopamine, we measured prolactin levels (by immuno-
radiometric assay; Biosource Technologies, Inc., Fleurus,
Belgium). HVA and 5-HIAA are cleared by the kidney so
we therefore assessed creatinine levels by using standard
laboratory methods. Because HVA is formed in close
conjunction with homocysteine synthesis (Fig. 1), we
measured plasma levels of total homocysteine and folate by
high-performance liquid chromatography (HPLC) as pre-
viously published (Giltay et al. 2003). Moreover, folate
may also be indirectly involved in rate-limiting enzymes
for dopamine and serotonin production through tetra-
hydrobiopterin (Bottiglieri et al. 2000).
To measure HVA and 5-HIAA, the major metabolite of
serotonin, samples were mixed with an equal volume of
perchloric acid (1 M) in order to precipitate proteins. After
centrifugation, the supernatant (250 µl) was loaded on a
Hypersil ODS HPLC column (Thermo Electron Corpo-
ration, Breda, The Netherlands) at 30 C. The mobile
phase consisted of ammonium acetate (0·02 M), sodium-
EDTA (0·25 mM), sodium chloride (6·5 mM) and metha-
nol (9·5%) at pH 4·95. The flow was set at 1·25 ml/min
by using an isocratic Sp8810 pump (Thermo Electron
Corporation). Detection was performed by using an
electrochemical detector (INTRO; Antec Leyden,
Zoeterwoude, The Netherlands; potential: 0·525 mV).
Chromatographic data were recorded by using PC1000
software (Thermo Electron Corporation). The intra-assay
coeﬃcient of variation (C.V.) for HVA was 2·0% at a
concentration of 156 nM (n=9) and interassay C.V. was
2·7% at a concentration of 160 nM (n=7). The intra-assay
C.V. for 5-HIAA was 3·8% at a concentration of 93 nM
(n=9) and the interassay C.V. was 5·5% at a concentration
of 55 nM (n=7).
Statistical analysis
Data are presented as means (with S.D.) or geometric means
(with percentiles: P10 and P90) for right-skewed data (i.e.
total homocysteine, folate and HVA). HVA and 5-HIAA
values were correlated with other variables using Spear-
man’s correlation coeﬃcient. For the comparison at base-
line between the two groups, a t-test for independent
samples or analysis of covariance was used. For MF
transsexuals, a two-factor repeated measures ANOVA
with interaction was used to study the eﬀects of estrogens
plus anti-androgens in time, as well as to compare the
eﬀects of the two treatment regimens in time. Post-hoc
comparisons were made using a Sidak test to identify
significant diﬀerences between time-points. For FM
transsexuals, a Student’s t-test for paired samples was used
to study the eﬀects of androgen administration in time. A
two-tailed P<0·05 was considered statistically significant.
The software used was SPSS 10·0, Chicago, IL, USA.
Results
Comparison between elderly men and women
Men were, on average, 72·5 years old (S.D. 4·9; range
65–84) and women were 72·8 years old (S.D. 5·8; range
65–83; for sex diﬀerence P=0·79). The BMI was a mean
of 24·6 (S.D. 3·0) in men and 26·1 (S.D. 5·0) in women (for
sex diﬀerence P=0·15). Plasma HVA levels were lower in
elderly men than postmenopausal women (geometric
mean 25·4 nmol/l (P10 4·9; P90 69·8) vs 39·0 nmol/l (19·0;
76·1); P=0·027). Plasma HVA was positively associated
with age (r=0·26, P=0·026). The sex diﬀerence for
plasma HVA remained present after adjusting for age
(P=0·033). Plasma 5-HIAA levels were similar in elderly
men and women (P=0·42), also when one outlier
(323 nmol/l) was excluded from the analysis (21·6 nmol/l
(S.D. 15·3) vs 21·9 nmol/l (S.D. 24·6); P=0·94).
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Intervention studies with sex steroids
Pretreatment values The mean age of MF transsex-
uals was 32·4 (S.D. 6·6; range 20–43) years with a BMI
of 22·8 (S.D. 2·7) kg/m2 and that of FM transsexuals
was 27·1 (S.D. 6·3; range 18–37) years with a BMI of 23·9
(S.D. 4·3) kg/m2. Of the MF transsexuals, nine (60%)
were smokers and of the FM transsexuals ten (59%)
were smokers.
In MF transsexuals, baseline HVA levels were
inversely associated with testosterone levels (r=– 0·61,
P=0·017) and LH levels (r=–0·70, P=0·003), whereas
baseline 5-HIAA levels were positively associated with
creatinine levels (r=0·53, P=0·050). Smokers had
significantly lower HVA levels as compared with
non-smokers (P=0·003), and similar levels of 5-HIAA
(P=0·18). In FM transsexuals, baseline HVA and
5-HIAA levels were not correlated with levels of
hormones, creatinine or folate, and baseline HVA levels
were not correlated with levels of total homocysteine.
Smokers had similar levels of HVA and 5-HIAA as
compared with non-smokers (P=0·50 and P=0·54
respectively). Age was unrelated to plasma HVA or
5-HIAA in either group (P>0·20).
At baseline, plasma HVA was significantly lower in
genetic men as compared with women (geometric mean
14·8 nmol/l (P10 7·0; P90 35·0) vs 34·3 (P10 21·8; P90
61·4); P<0·0005; Fig. 2 and Table 1). The sex diﬀer-
ence remained present (P=0·003) after adjusting for age,
Figure 2 Individual values of HVA on a logarithmic scale and 5-HIAA in 15 MF
transsexuals (d) at baseline and after 2 and 4 months of administration of ethinyl estradiol
plus cyproterone acetate and 17 FM transsexuals ([) at baseline and after 4 months of
administration of testosterone esters. Back-transformed mean values (with confidence
intervals) at 0 and 4 months are identified by diamonds. P values were assessed by
ANOVA for repeated measurements for MF transsexuals and by t-test for paired
samples for FM transsexuals. At baseline, sex differences were statistically significant for
plasma HVA (P<0·0005) and not for 5-HIAA (P=0·981). At 4 months, the sex difference
remained statistically significant for plasma HVA (P=0·003).
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smoking status, BMI and creatinine levels as covariates.
No sex diﬀerence was found for 5-HIAA (P=0·981; Fig.
2 and Table 1).
Eﬀects of cross-sex hormone administration In
MF transsexuals, estrogen administration substantially
decreased serum levels of testosterone, LH and FSH,
whereas prolactin levels increased. The synthetic estrogen,
ethinyl estradiol, could not be detected by the 17-
estradiol assay used (Table 1). There were no significant
eﬀects on plasma HVA and 5-HIAA (Fig. 2 and Table 1),
although the change in plasma 5-HIAA was of borderline
significance (P<0·10), though quantitatively small. The
proportional increase in prolactin or decrease in testoster-
one, LH, FSH and total homocysteine were not related to
proportional changes in plasma HVA or 5-HIAA.
In FM transsexuals, testosterone administration in-
creased serum levels of testosterone and creatinine levels,
while serum levels of 17-estradiol, LH and FSH were
suppressed. Partly reflecting the anabolic eﬀects, there
were increases in BMI, lean body mass and plasma
creatinine and homocysteine. Again, there were no sig-
nificant eﬀects on plasma HVA and 5-HIAA (Fig. 2),
although there was a tendency for plasma 5-HIAA to
increase of borderline significance (P=0·074; Table 1).
The proportional changes in hormones, total homocysteine
and creatinine were not related to the proportional
changes in plasma HVA or 5-HIAA.
When baseline and 4-month values were used, there
was no treatment eﬀect when the two groups were
combined in an ANOVA for repeated measurements,
either for HVA (P=0·79) or for 5-HIAA (P=0·21). Thus,
the eﬀects of estrogen plus anti-androgen administration
were not significantly diﬀerent from the eﬀects of testos-
terone administration. After 2 and 4 months of estrogen
plus anti-androgen administration, smoking MF trans-
sexuals still had lower plasma HVA levels as compared
with non-smoking MF transsexuals (P<0·01). After 4
months of cross-sex hormone administration, there was
still a lower mean level of plasma HVA in MF trans-
sexuals (genetic men) as compared with FM transsexuals
(genetic women) (15·2 nmol/l (P10 6·1; P90 37·5) vs 31·7
(P10 14·6; P90 72·7); P=0·003; Fig. 2 and Table 1).
Discussion
Subjects in our study were (1) elderly men and postmeno-
pausal women and (2) adult eugonadal genetic male and
female transsexuals with sex-appropriate levels of sex
steroids. In previous studies, women were found to have
higher plasma levels of HVA than men (Bowers et al.
1983, Glazer et al. 1983, Bowers & Swigar 1987, Koreen
et al. 1994, Davila et al. 1995, Szymanski et al. 1995,
Sumiyoshi et al. 1997b), which could hypothetically be
ascribed to their respective diﬀerences in sex steroidTa
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milieus. However, this idea is not supported by our data.
First, HVA levels in plasma were lower in elderly men
than in postmenopausal women. This suggested that the
sex diﬀerence is not aﬀected by the decline in sex steroid
levels as the physiological manifestations of aging, particu-
larly following menopause. Remarkably enough, aging
men have higher circulating levels of estradiol than post-
menopausal women (Vermeulen et al. 2002). Secondly,
administration of a high dose of oral ethinyl estradiol plus
cyproterone acetate to genetic men and of testosterone to
genetic women did not aﬀect plasma HVA. Therefore, the
male/female diﬀerence in plasma HVA cannot be ex-
plained by the male/female diﬀerence in sex steroid
milieus, although an inverse correlation between HVA
and testosterone levels was found in the genetic male
group at baseline. These results are in line with the
findings that testosterone administration in healthy young
men did not aﬀect HVA levels (Hannan et al. 1991), that
women with polycystic ovary syndrome, which is associ-
ated with hyperandrogenism, have similar plasma levels of
catecholamines and urinary levels of HVA as compared
with female controls (Garcia-Rudaz et al. 1998), and that
estrogen administration to postmenopausal women did not
aﬀect urinary HVA levels (Lobo et al. 1984).
What mechanism may explain the sex diﬀerence in
HVA? Since sex steroids did not aﬀect HVA, a putative
explanation may be a sex diﬀerences in gene expression.
MAO A and especially MAO B are responsible for the
oxidative deamination of dopamine (Fig. 1), and are both
coded for on the X chromosome (i.e. Xp11 region). There
is evidence that MAO A and especially MAO B escape
X-chromosome inactivation (Good et al. 2003). Since
(genetic) women have two X chromosomes and MAO
may be expressed from both X chromosomes, this would
result in higher MAO activity and consequently higher
HVA levels in women then in men. Alternatively, there
are sex diﬀerences in the brain which develop and mature
until early adulthood (Gogtay et al. 2004) and sex steroids
may have produced lasting, so-called organizational, ef-
fects on dopamine-producing tissue during fetal, perinatal
and pubertal periods. Previous studies in transsexuals also
suggest that sexually dimorphic brain structures are resist-
ant to exposure to cross-sex hormones and are not
influenced by gonadal steroids during adulthood, but they
have rather originated by direct action of the genetic
factors (e.g. diﬀerence in gene dosage) or by the organi-
zational eﬀects of gonadal steroids during early develop-
ment (Zhou et al. 1995, Kruijver et al. 2000).
We found that MF transsexuals who were smokers
had significantly lower plasma HVA as compared with
non-smokers, which is in accordance with the finding that
male smokers had lower cerebrospinal fluid levels of HVA
(Geracioti et al. 1999). Cigarette smoke may have substan-
tially inhibited the central nervous system MOA activity,
leading to increased dopaminergic activity (Fig. 1) (Brody
et al. 2004) as well as lower plasma HVA. Alternatively,
men with low HVA levels may be more prone to become
smokers (i.e. reverse causation). The increase in prolactin
levels in MF transsexuals upon estrogen administration
is likely the reflection of a direct estrogenic enhancement
or lower dopaminergic inhibitory eﬀects on prolactin
secretion. In previous studies in postmenopausal women,
estrogen replacement therapy increased prolactin and
cortisol responses to the serotonin agonist metachloro-
phenylpiperazine (Halbreich et al. 1995) and hormone
replacement therapy increased prolactin secretion in re-
sponse to the dopamine-blocking agent sulpiride (Paoletti
et al. 2001). The findings were thought to reflect changes
in serotonergic and dopaminergic activity upon estrogen
administration (Halbreich et al. 1995, Paoletti et al. 2001).
These estrogenic eﬀects may be confined to the pituitary
gland and the hypothalamic structures that control the
pituitary production of prolactin, but the eﬀects of sex
hormones are likely to diﬀer from one brain region to
another. Dopamine degradation proceeds by MOA and
COMT, which catalyze the transfer of a methyl group
from methionine to dopamine, resulting in homocysteine
and HVA (Fig. 1). Because the synthetic pathways are
coupled, it is of note that the profound decrease and
increase in plasma total homocysteine in MF and FM
transsexuals respectively (Giltay et al. 2003) were not
paralleled by changes in plasma HVA.
Methodologically, the use of plasma levels of HVA has
its limitations. Plasma levels of HVA are dependent upon
the balance between both delivery into the plasma and
clearance from the plasma (half-life: 40 min) (Goldstein
et al. 2003). Only 12–40% of HVA in plasma is of central
nervous system origin (Swann et al. 1980, Maas et al. 1988,
Lambert et al. 1991, Lambert et al. 1993, Amin et al. 1995,
1998); much more is derived from central and peripheral
sympathetic nerves and the adrenal medulla. It is possible
that sex steroids aﬀected biosynthesis, transport, concen-
tration, uptake, receptor potentiation and density, post-
synaptic responsivity, blood–brain barrier, degradation, or
clearance of dopamine and serotonin (Halbreich & Kahn
2001). Potential eﬀects on dopamine and serotonin activity
may have been obscured by compensatory (i.e. negative
feedback) mechanisms, and by the indirect assessment of
monoamine status in plasma samples. Finally, alterations in
renal clearance may cause concomitant changes in the
plasma HVA. However, the increase in plasma creatinine
upon testosterone administration is not caused by a de-
crease in renal function, since creatinine clearance was
unaﬀected by testosterone administration in another study
of cross-sex hormone administration to transsexuals (Giltay
et al. 1998). The increase in plasma creatinine is rather a
reflection of the anabolic eﬀect of testosterone in genetic
females, as indicated by the increase in lean body mass.
The interpretation of our results is limited by the
inclusion of a relatively small numbers of subjects. Fur-
thermore, the intervention study had a relatively short
follow-up of 4 months, had an open-label design and
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lacked a true placebo group, due to the nature of the study
population and the treatment indication. Moreover, dif-
ferent eﬀects may have been found in hypogonadal men
and women undergoing sex-appropriate hormone replace-
ment. Yet, the dose of cross-sex hormone administration
was high and the levels of HVA were consistently lower in
men than in women as well as in MF transsexuals than
in FM transsexuals, both before and after cross-sex
hormone administration.
We found that fasting plasma levels of HVA, the major
metabolites of dopamine, was not significantly changed by
administration of high-dose cross-sex hormone admin-
istration in FM and MF transsexual subjects. Our
results have suggested that the sex diﬀerence in plasma
HVA – with higher HVA levels in females than in males
– is related to mechanisms other than exposure to sex
steroids in adulthood, and may rather be the result of a
sex diﬀerence in genetic factors or of organizing eﬀects
of sex hormones during early development.
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